Silicon Valley Capital Partners’s Takeda Pharmaceutical TAK Stock Holding History

Silicon Valley Capital Partners’s Portfolio TAK Stock Details TAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$722	Buy	+39	New	+$684	﹤0.01%	352

Other funds holding TAK

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BIP

Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Silicon Valley Capital Partners's TAK Position: Q1 2026 in Review

Silicon Valley Capital Partners opened a new position in Takeda Pharmaceutical (TAK) in Q1 2026: 39 shares worth $722. The stake represents ﹤0.01% of the portfolio and ranks #352 among its holdings.

361 funds tracked by Wall St. Rank hold TAK as of Q1 2026.

Silicon Valley Capital Partners held 39 shares of Takeda Pharmaceutical worth $722 as of Q1 2026.
Takeda Pharmaceutical was a new Silicon Valley Capital Partners position in Q1 2026.
Takeda Pharmaceutical made up ﹤0.01% of Silicon Valley Capital Partners's portfolio in Q1 2026, its #352 holding.
361 funds tracked by Wall St. Rank held Takeda Pharmaceutical as of Q1 2026.

Based on Silicon Valley Capital Partners's 13F filing for Q1 2026, filed 19 May 2026.